title: Hodgkin's disease. Prognostic value of Gallium-67 scintigraphy.
abstract: OBJECTIVE
  The aim of this study is to assess the clinical impact of gallium-67 scintigraphy, before and after treatment, in patients with Hodgkin's disease, and to compare the overall survival between the patients whose gallium studies after treatment were negative and those whose studies remained positive.
  
  
  METHODS
  We have studied 75 patients (40 women, 35 men) with Hodgkin's disease. All the patients underwent (67)Ga scintigraphy at the moment of the diagnosis (basal study) and in the case that basal study was positive (abnormal hyper-uptake focus) we performed follow-up studies after the treatment. We have calculated the overall survival among patients whose studies after treatment were negative (1(st) group) and those whose studies remained positive (2(nd) group) and between patients whose studies were negative at diagnosis (3(rd) group).
  
  
  RESULTS
  Gallium scintigraphy was positive at diagnosis in 47 patients (62.6%). In 39 of them we were able to perform the follow-up study after treatment. The follow-up study was negative in 31 patients while in 8 patients the gallium scintigraphy remained positive. The overall survival was significantly higher (p<0.001) in the 1(st) group compared with the 2(nd) group. The overall survival was higher in the 1(st) group compared with the 3(rd) but statistic significance level was not reached.
  
  
  CONCLUSIONS
  Our data suggest that: 1) in Hodgkin's disease (67)Ga scintigraphy is useful to establish the diagnosis of complete remission; 2) if the gallium scan remains positive after treatment, the prognosis of patients is worse than the prognosis of patients with a negative scan.
authors.affiliation: Department of Nuclear Medicine, La Fe University Hospital, Valencia, Spain.
authors.forename: I
authors.initials: I
authors.lastname: Hervás
authors.forename: A
authors.initials: A
authors.lastname: Segura
authors.forename: P
authors.initials: P
authors.lastname: López-Tendero
authors.forename: P
authors.initials: P
authors.lastname: Bello
authors.forename: P
authors.initials: P
authors.lastname: González-Cabezas
authors.forename: D
authors.initials: D
authors.lastname: Flores
authors.forename: A
authors.initials: A
authors.lastname: Yuste
authors.forename: R
authors.initials: R
authors.lastname: Pérez-Velasco
authors.forename: R
authors.initials: R
authors.lastname: Girones
authors.forename: A
authors.initials: A
authors.lastname: Mateo
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002951:Citrates; D005260:Female; D005708:Gallium; D006689:Hodgkin Disease / Q000000981:diagnostic imaging* / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D013030:Spain / Q000453:epidemiology; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D002951:Citrates; D019275:Radiopharmaceuticals; D005708:Gallium; C103850:gallium citrate